Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.25 USD | +2.11% |
|
+8.70% | +19.44% |
Jul. 09 | Amneal Pharmaceuticals, Inc. Launches FOCINVEZ, the First Ready-to-Use Version of Fosaprepitant | CI |
Jul. 01 | Amneal Pharmaceuticals to Develop Omalizumab Biosimilar for Allergy Treatments | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.44% | 2.19B | |
+60.25% | 846B | |
+38.56% | 628B | |
-4.49% | 360B | |
+18.30% | 322B | |
+9.64% | 297B | |
+14.15% | 240B | |
+3.11% | 224B | |
+16.98% | 223B | |
+12.87% | 173B |
- Stock Market
- Equities
- AMRX Stock
- News Amneal Pharmaceuticals, Inc.
- Transcript : Amneal Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 11